- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04944290
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
March 9, 2023 updated by: Padagis LLC
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to Simbrinza® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
447
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27101
- James D. Branch Ophthalmology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes
- Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
- Adequate wash-out period prior to baseline of any ocular hypotensive medication.
- Baseline (Day 0/hour 0) pressure ≥ 22 mm Hg and ≤ 34 mm Hg in each eye and any asymmetry of pressure between the eyes no greater than 5 mm Hg.
- Baseline best corrected visual acuity equivalent to 20/200 or better in each eye
Exclusion Criteria:
- Females who are pregnant, breast feeding, or planning a pregnancy.
- Females of childbearing potential who do not agree to utilize an adequate form of contraception
- Current, or past history of, severe hepatic or renal impairment
- Current, or history within two months prior to baseline of, significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye
- Current corneal abnormalities that would prevent accurate readings with the Goldmann applanation tonometer
- Functionally significant visual field loss
- Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
- Use at any time prior to baseline of an intraocular corticosteroid implant
- Use within one week prior to baseline of contact lens
- Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid
- Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy
- Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid
- Having undergone within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)
- Having undergone within twelve months prior to baseline refractive surgery, filtering surgery, or laser surgery for pressure reduction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Perrigo active
|
Test product
|
Active Comparator: Reference active
|
Reference product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in intra-ocular pressure
Time Frame: 6 weeks
|
mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m.
(hour 0; before the morning drop) and approximately 10:00 a.m.
(hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 28, 2021
Primary Completion (Actual)
March 11, 2022
Study Completion (Actual)
June 21, 2022
Study Registration Dates
First Submitted
June 11, 2021
First Submitted That Met QC Criteria
June 25, 2021
First Posted (Actual)
June 29, 2021
Study Record Updates
Last Update Posted (Actual)
March 13, 2023
Last Update Submitted That Met QC Criteria
March 9, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Glaucoma
- Glaucoma, Open-Angle
- Ocular Hypertension
- Hypertension
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Brimonidine Tartrate
- Brinzolamide
Other Study ID Numbers
- PRG-NY-20-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Brinzolamide/brimonidine ophthalmic suspension
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchTerminatedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompleted
-
Padagis LLCCompletedOcular Hypertension | Glaucoma, Open-AngleUnited States
-
Alcon ResearchTerminatedOcular Hypertension | Open-angle GlaucomaUnited States